Monopar Therapeutics shares technical analysis: $120.21 resistance in focus after rally
Monopar Therapeutics (MNPR) stock is trading at $115.47, up 3.16% on the day and holding above its key moving averages. The price remains well supported relative to recent trends, reflecting a continuation of upward momentum.
71.3350
79.4350
Highlights
- MNPR/USD is in a bullish technical structure, trading firmly above short-, medium-, and long-term moving averages.
- Momentum is mixed, with buyer dominance and overbought readings but some oscillators showing divergence and stretched conditions.
- The expected trading range for the next several days is $110.73 to $120.21, with a 75% probability of further upside.
Technical overextension emerges as overbought signals warn of reversal risk
On the hourly chart, MNPR is above the MA-20 at $111.22 and MA-50 at $111.03, while on the daily timeframe it is significantly above the MA-200 at $74.38. The Ichimoku Kijun line at $112.07 has established a clear support. Momentum indicators reveal RSI at 58.59 (Buy), with both MACD and ADX in neutral zones. Stochastic RSI, CCI, and Bull/Bear Power highlight overbought territory and sustained buyer dominance, while the Awesome Oscillator shows strong upside conditions. Despite robust buying, the presence of overbought oscillators suggests momentum may be stretched, introducing potential for near-term divergence.
Sideways consolidation likely as breakout and pullback odds diverge
Over the next several days, MNPR is likely to trade within a $110.73 to $120.21 range, representing a typical volatility band relative to current levels. There is a 75% probability of continued upside, while the chance of a pullback is 25%. The baseline scenario anticipates consolidation within a sideways channel; a breakout above resistance may drive further gains, whereas a dip below support would increase downside risk.
Earlier, analysts noted that Monopar Therapeutics was exhibiting technical resilience amid mixed momentum signals and short-term selling pressure. The current price action confirms ongoing strength while highlighting that traders should monitor for near-term reversals if overbought conditions persist.
Latest Monopar Therapeutics News
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
